NRX Pharmaceuticals, Inc.

Biotechnology • Healthcare • Wilmington, DE, United States • NRXPW (NCM)

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.

484 254 6134 1201 Orange Street, Wilmington, DE 19801, United States

Stock Performance (90 Days)

Data through Dec 29, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

NRx Pharmaceuticals Completes Debt Repayment, Ends 2025 Debt-Free - TipRanks

TipRanks • Dec 29

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

Yahoo Finance • Nov 17

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - GlobeNewswire

GlobeNewswire • Dec 18

NRx Pharmaceuticals, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Investing News Network

Investing News Network • Nov 17

HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq

Nasdaq • Dec 16

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has NRX Pharmaceuticals, Inc. had layoffs?

No layoff events have been recorded for NRX Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

What industry is NRX Pharmaceuticals, Inc. in?

NRX Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is NRX Pharmaceuticals, Inc. a publicly traded company?

Yes, NRX Pharmaceuticals, Inc. is publicly traded under the ticker symbol NRXPW on the NCM.

Where is NRX Pharmaceuticals, Inc. headquartered?

NRX Pharmaceuticals, Inc. is headquartered in Wilmington, DE, United States at 1201 Orange Street, Wilmington, DE 19801, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.